CAS: 91-33-8; Benzthiazide

该化合物是一种硫酸二甲酸酯,主要用于治疗高血压和与心脏衰竭等各种条件相关的水肿,其特点是化学结构,包括一个苯环,它与硫酸酯混合物结合,有助于其药理特性.该物质一般是白色的,白色的,白色的晶状粉,在水中略有溶解,在有机溶剂中更易溶解.苯并二氮的功能是抑制肾脏溶液管管内再次吸附钠,导致钠和水的排泄增加,从而减少血量和血压.其作用机制还具有轻微的血管效应.该化合物的毒性特征相对较低,但与其他亚氨酸性物质一样,它可能造成电解性失衡,特别是低血糖.苯并经常通过口服,并可能与其他抗合用药剂结合使用,以提高治疗功效.正如任何药物一样,对侧面效果和相互作用的监测是关键治疗期间的基本效果和相互作用.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-12146136-B2
    优先权日:2020-03-26
    标题:Synthesis of modified oligonucleotides with increased stability
    发明人:KHVOROVA ANASTASIA; ROUX LOÃ?C MAURICE RENÉ JEAN; YAMADA KEN
    权利人:UNIV MASSACHUSETTS
    摘要:This disclosure relates to the synthesis of novel modified oligonucleotides. The synthesis of novel phosphoramidites are also provided.

    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-10227616-B2
    优先权日:2014-04-16
    标 题 :Process for the production of 1,4-butanediol
    发明人:DANI MARIA; RUGGIERO GIUSEPPE; PERINI DAVIDE; BIANCHI ALICE
    权利人:NOVAMONT SPA; GENOMATICA INC
    摘要:Process for the synthesis of 1,4-butanediol comprising fermentation of a culture medium by a microorganism provided with at least one metabolic pathway for the synthesis of 1,4-butanediol and able to use saccharose, in which said culture medium comprises a glucose and saccharose mixture comprising, based on the combined weight of glucose and saccharose, 10-90% by weight of saccharose and 10-90% by weight of glucose.

    专利号:US-12295961-B2
    优先权日:2009-12-31
    标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
    发明人:DHINGRA OM
    权利人:MARIUS PHARMACEUTICALS INC
    摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

    专利号:US-2024117398-A1
    优先权日:2021-01-20
    标 题:Production of oligosaccharides comprising ln3 as core structure in host cells
    发明人:AESAERT SOFIE; BEAUPREZ JOERI; PETERS GERT; VERCAUTEREN ANNELIES
    权利人:INBIOSE NV
    摘要:Described is a method of producing an oligosaccharide comprising a lacto-N-triose (LN3; GlcNAc-beta1,3-Gal-beta1,4-Glc) as a core trisaccharide by cultivation with a genetically modified cell, as well as the genetically modified cell used in the method. The genetically modified cell comprises at least one nucleic acid sequence coding for a galactoside beta-1,3-N-acetylglucosaminyltransferase and a glycosyltransferase involved in the synthesis of an oligosaccharide comprising LN3 as a core trisaccharide and at least one nucleic acid sequence expressing a membrane protein. Furthermore, the present invention provides for a purification of the oligosaccharide comprising LN3 as a core trisaccharide from the cultivation.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Adler RA, Costanzo LS, Stauffer ME. Hypercalciuria in hyperprolactinemic rats: effects of benzthiazide. Metabolism. 1986 Jul;35(7):668-72. French. Danish. French.
    11: EDGE JR, ADISESH LT. COMBINED BENZTHIAZIDE AND TRIAMTERENE FOR RESISTANT EDEMA. Appl Ther. 1965 Feb;7:117-9. French. French. French. French. French. French. French.

    合成参考文献


    参考文献:10.1007/s00216-010-3484-3
    摘要:Peters RJB, Oosterink JE, Stolker AAM, Georgakopoulos C, Nielen MWF. Generic sample preparation combined with high-resolution liquid chromatography–time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. Analytical and Bioanalytical Chemistry. 2010 Feb 16;396(7):2583–98. doi: 10.1007/s00216-010-3484-3.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知